Knight Therapeutics Announces Launch of WYNZORA® in Canada

MONTREAL, Aug. 20, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today the launch of WYNZORA®, a uniform white aqueous cream containing 0.05 mg/g of calcipotriol (CAL) and 0.5 mg/g of betamethasone dipropionate (BDP), in Canada. WYNZORA® is indicated for the topical treatment of psoriasis vulgaris in […]